Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Trial Profile

A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELX 02 (Primary) ; ELX 02 (Primary)
  • Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eloxx Pharmaceuticals
  • Most Recent Events

    • 08 Mar 2019 According to an Eloxx Pharmaceuticals media release, results from the phase 1a single-ascending dose (SAD) study for ELX-02 (NCT02807961 and NCT03292302) have been published in the January 2019 edition of the Journal of Clinical Pharmacology and Drug Development.
    • 08 Nov 2018 According to an Eloxx Pharmaceutical media release, the results have been submitted to a scientific journal for publication.
    • 19 Mar 2018 According to an Eloxx Pharmaceutical media release, results from the completed Phase 1 SAD study (NCT02807961 and NCT03292302) will be included in the planned IND and CTA submissions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top